



**NEWS
release**

Enzo Biochem, Inc.
527 Madison Avenue
New York, NY 10022

For Immediate Release

Contact: *Barry Weiner*
(212) 583-0100

**ENZO DIAGNOSTICS TO SUPPLY REAGENTS
FOR USE WITH GENE LOGIC FLOW-THRU CHIPS™**

COMPANY ANNOUNCES LIMITED USE AGREEMENT

FARMINGDALE, NY, March 23, 1999 – Enzo Diagnostics, Inc. (ASE:ENZ) announced that it has concluded an agreement with Gene Logic, Inc. (NASDAQ:GLGC) under which Enzo will be the exclusive supplier of its patented reagent products for labeling and detecting gene sequences with Gene Logic Flow-thru Chip™ probe arrays. Under the agreement Gene Logic will be afforded limited access to Enzo's patented and proprietary products and technology for internal use in developing gene expression data, profiles and genetic databases for research purposes.

"Gene Logic is a genomics company with a significant position in biodata, particularly gene expression information," commented Dr. Dean L. Engelhardt, Enzo's Senior Vice President. "Clearly, our proprietary nonradioactive nucleic acid labeling, hybridization and detection technology and products complement quite well with Gene Logic's efforts in this area. This is an important first step in building a working relationship between the two companies. We are presently exploring other areas of mutual interest."

"The relationship with Enzo Diagnostics will facilitate the development of Gene Logic's chip-based programs," said Larry Tiffany, Gene Logic's Director for Technology and Intellectual Property Development.

Enzo Biochem is engaged in the research, development and manufacture of innovative health care products based on molecular biology and genetic engineering techniques, and in providing diagnostic services to the medical community. The Company currently manufactures over 200 products utilized in various aspects of molecular biological research. Its proprietary non-radioactive labeling and detection technologies are being utilized by researchers and companies worldwide.

Gene Logic combines genomic technologies and bioinformatic expertise to provide pharmaceutical companies with products designed to reduce the time, cost, and risk associated with drug discovery and development. These products include proprietary databases of gene expression for drug target discovery and toxicology, a novel screening technology for identifying new drug leads, and a pharmacogenomic technology for improving drug effectiveness. Gene Logic's Data Logic division, based in Berkeley, CA, develops and markets bioinformatic software for managing and integrating genomic data.

Except for historical information, the matters discussed in this news release may be considered "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements include declarations regarding the intent, belief or current expectations of the Company and its management. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties that could materially affect actual results.

* * * * *